Vanguard Group Inc. Buys 1,992,898 Shares of Hologic Inc. (HOLX)
Vanguard Group Inc. increased its stake in shares of Hologic Inc. (NASDAQ:HOLX) by 8.1% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 26,537,173 shares of the company’s stock after buying an additional 1,992,898 shares during the period. Vanguard Group Inc. owned 9.57% of Hologic worth $918,185,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of the stock. State Street Corp boosted its stake in Hologic by 26.4% in the first quarter. State Street Corp now owns 10,295,836 shares of the company’s stock valued at $355,210,000 after buying an additional 2,150,544 shares during the period. Prudential Financial Inc. boosted its stake in Hologic by 37.5% in the second quarter. Prudential Financial Inc. now owns 3,613,781 shares of the company’s stock valued at $125,036,000 after buying an additional 986,320 shares during the period. Norges Bank acquired a new stake in Hologic during the fourth quarter valued at about $98,031,000. Dimensional Fund Advisors LP boosted its stake in Hologic by 4.3% in the second quarter. Dimensional Fund Advisors LP now owns 2,516,727 shares of the company’s stock valued at $87,074,000 after buying an additional 103,939 shares during the period. Finally, Geode Capital Management LLC boosted its stake in Hologic by 54.3% in the first quarter. Geode Capital Management LLC now owns 2,328,326 shares of the company’s stock valued at $80,187,000 after buying an additional 819,646 shares during the period. 94.51% of the stock is owned by hedge funds and other institutional investors.
Shares of Hologic Inc. (NASDAQ:HOLX) opened at 39.06 on Friday. Hologic Inc. has a one year low of $31.84 and a one year high of $41.66. The stock has a market capitalization of $10.84 billion, a P/E ratio of 43.07 and a beta of 1.03. The firm’s 50-day moving average price is $38.36 and its 200-day moving average price is $35.88.
Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, July 27th. The company reported $0.51 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.03. Hologic had a return on equity of 26.25% and a net margin of 9.39%. The company had revenue of $717.40 million for the quarter, compared to analyst estimates of $703.66 million. During the same quarter in the prior year, the company posted $0.43 EPS. The business’s revenue for the quarter was up 3.4% compared to the same quarter last year. Equities research analysts anticipate that Hologic Inc. will post $1.94 EPS for the current fiscal year.
HOLX has been the subject of several recent analyst reports. Barclays PLC reissued a “hold” rating and set a $42.00 target price on shares of Hologic in a research note on Sunday, July 10th. Bank of America Corp. reaffirmed a “buy” rating on shares of Hologic in a research note on Wednesday, June 22nd. Jefferies Group reaffirmed a “buy” rating and issued a $42.00 price objective on shares of Hologic in a research note on Tuesday, June 21st. Zacks Investment Research raised Hologic from a “hold” rating to a “buy” rating and set a $39.00 price objective for the company in a research note on Friday, July 1st. Finally, Royal Bank Of Canada lifted their price objective on Hologic from $37.00 to $39.00 and gave the company a “sector perform” rating in a research note on Monday, August 1st. Seven research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $42.47.
In other news, Director Nancy Leaming sold 8,179 shares of the company’s stock in a transaction on Thursday, July 21st. The stock was sold at an average price of $37.00, for a total transaction of $302,623.00. Following the completion of the sale, the director now directly owns 67,140 shares in the company, valued at approximately $2,484,180. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.84% of the company’s stock.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.